Horn C R, Clark T J, Cochrane G M
Department of Thoracic Medicine, United Medical School, Guy's Hospital, London, U.K.
Respir Med. 1990 Jan;84(1):61-6. doi: 10.1016/s0954-6111(08)80096-0.
A community based, prospective study of the value of high dose inhaled therapy for the reduction of the morbidity of asthma has been undertaken. One hundred and sixty adults with airflow obstruction were treated for up to 9 months with increasing doses of salbutamol. Two thirds of the patients also received increasing doses of beclomethasone dipropionate in a 'partially double-blind' manner. The FEV1 rose by at least 10 per cent of that predicted in one third of the total patients and the overall mean domiciliary peak expiratory flow rates rose by approximately 50 l/min-1. All chronic symptoms were abolished in half of the patients and acute attacks of asthma in the majority. Asthma was controlled in a greater proportion of patients more effectively and rapidly by a combination of inhaled steroids and beta agonist than by salbutamol alone, particularly when inhaled steroids were started in relatively high dosage.
开展了一项基于社区的前瞻性研究,以探讨高剂量吸入疗法对降低哮喘发病率的价值。160名有气流阻塞的成年人接受了长达9个月的沙丁胺醇递增剂量治疗。三分之二的患者还以“部分双盲”方式接受了丙酸倍氯米松递增剂量治疗。三分之一的患者FEV1升高至少达到预测值的10%,总体平均家庭呼气峰值流速升高约50升/分钟。一半的患者所有慢性症状消失,大多数患者哮喘急性发作得到控制。与单独使用沙丁胺醇相比,吸入性类固醇和β受体激动剂联合使用能更有效、更迅速地控制更大比例患者的哮喘,特别是当以相对高剂量开始使用吸入性类固醇时。